Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
21,000,000 plus shares traded and counting.
Most of the concerns are based upon a very small Phase 2 group and no control group. Yet they are still moving forward with Phase 3 trials.
https://www.forbes.com/sites/matthewherper/2018/06/02/nektar-and-bristol-hurtle-forward-with-experimental-cancer-drug/#6986c24445b6
I wouldn't try to catch the falling knife today but over the next 90 days I think the stock will recover up to the 70 area.
Some questions/concerns raised over this data released for ASCO... I think we'll be giving back most of Friday gains come Monday. Hopefully, i am sorely incorrect.
long time without any momentum... this is a new and unwelcome trend for us- where and when is that NDA filing happening?
This means BMY can now start enrolling patients in multiple pivotal trials of Opdivo + NKTR-214, as previously described.
It's official...
Nektar Therapeutics Announces Effective Date of Global Development & Commercialization Collaboration with Bristol-Myers Squibb
SAN FRANCISCO, April 3, 2018 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) announced today that the waiting period has expired under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and the previously-announced Strategic Collaboration Agreement between Nektar and Bristol-Myers Squibb Company is now effective. The global development and commercialization collaboration for Nektar's CD122-biased agonist, NKTR-214, was announced on February 14, 2018.
Upon the collaboration agreement becoming effective on April 3, 2018, Bristol-Myers Squibb made a non-refundable upfront cash payment of $1.0 billion to Nektar. In addition, Bristol-Myers Squibb paid the purchase price of $850 million to Nektar for the sale and issuance by Nektar of 8,284,600 shares of its common stock to Bristol-Myers Squibb pursuant to a share purchase agreement entered into concurrently with the collaboration agreement.
About Nektar Therapeutics
Nektar Therapeutics is a biopharmaceutical company with a robust, wholly-owned R&D pipeline of investigational medicines in oncology, immunology and pain as well as a portfolio of approved partnered medicines. Nektar is headquartered in San Francisco, California, with additional operations in Huntsville, Alabama and Hyderabad, India. Further information about the company and its drug development programs and capabilities may be found online at http://www.nektar.com.
Contacts (for Nektar):
Investors:
Jennifer Ruddock of Nektar Therapeutics
415-482-5585
Media:
Dan Budwick of Pure Communications, Inc.
(973) 271-6085
dan@purecommunicationsinc.com
On 3/19 NKTR moves to S&P 500 from the S&P Small Cap600.
We should see some volatility as much larger S&P funds jump in during the annual rebalancing.
A consolidation at 100 would be good for the stock but presentations and interim test results could give spikes as more people and funds find out about this company.
That’s a tricky call . They have a whole bunch of other drugs, some with different partners.
Buying out the company would require a major pharma to work with other major pharma’s which I just don’t see.
Do we expect the buyout before or after June? Over or under $200/share? Interested in everyone's thoughts.
Thanks,
Thanks but I think you posted the wrong presentation.
Here is the correct one:
http://files.shareholder.com/downloads/NKTR/5852742568x0x968306/0CF92912-858E-40D4-B317-46DD676BC348/NKTR-JPMorgan_2018.pdf
First significant gap and crap this morning. The spinning top of the candlestick is there for all to see. Question remains for today is if all the buying yesterday was blow off short covering with some presentation buying or if the selling today is just profit taking by some of the funds that were here in the $20-30's.
Would expect to see some analyst price target upgrades here in the next few days. Me thinks that $74 is the short term high for the next few months.
NKTR +20% .Must be some good stuff being said
President and Chief Executive Officer, Howard W. Robin, will make a presentation at the upcoming 36th Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 9, 2018, at 11:00 a.m. Pacific Time
The march higher continues as funds keep pouring money into the stock.
The head fake close yesterday under 50 was the set up for today big move. You didn't think all those big funds who bought the last few weeks over 50 were going to let this stock go down.
If the cancer drugs are really as good as the test results are showing, this stock could be a 5-10 bagger from these levels. Company would probably get bought out first imo.
Watch the money flow. Big boys still piling in. That cancer drug must be something special.
$NKTR breaks under 45 maybe we start our first down in a while
The two Form 4's filed here shows that the SVP's couldn't wait exercise and sell their shares. Earnings came out after market on 11/7/17 yet they were selling on 11/6, 11/7, and 11/8. Thought there was a blackout period where insiders couldn't sell shares within 5 days of earnings.
They turned out to be wrong as well as the stock took off and they lost potential profits.
Lol Abe been here no brainer
Finally this stock has broken out of it's base...owned it a long time ....since the Afrezza days.....
Booooooooom im back on it.....
Booooooom im back on it.
Up she goed
Nice trafding 30$ soon...
This one is a keeper starkd
Glad I put 11k in here yeehaw...nice hedge with my mmj plays
These analysts upgrading to the sky only for them to support a secondary at 1/4 of price..typical bio pump after any level of success
Nektar Therapeutics
Mar 20, 2017
NKTR-181 Meets Primary and Secondary Endpoints in Phase 3 SUMMIT-07 Study in Chronic Pain
NKTR-181 Significantly Reduced Pain in Patients with Moderate to Severe Chronic Low Back Pain
Primary Efficacy Endpoint Achieved (p=0.0019)
Analyst Conference Call and Webcast Today at 5:45 a.m. PDT/8:45 a.m. EDT
SAN FRANCISCO, March 20, 2017 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced positive results from the SUMMIT-07 Phase 3 efficacy study of NKTR-181, a first-in-class opioid analgesic. NKTR-181 is a new chemical entity (NCE) that is the first full mu-opioid agonist molecule designed to provide potent pain relief without the high levels of euphoria that can lead to abuse and addiction with standard opioids.1 The U.S. Food and Drug Administration (FDA) has granted the investigational medicine NKTR-181 Fast Track designation for the treatment of moderate to severe chronic pain.
"The data from this efficacy study are extremely important because they demonstrate that NKTR-181 produces strong analgesia in patients suffering from chronic pain while NKTR-181 has also demonstrated significantly lower abuse potential than oxycodone in a human abuse potential study," said clinical investigator Martin Hale, M.D., medical director of Gold Coast Research. "While standard opioid analgesics, including abuse-deterrent formulations, have been the most effective way to treat chronic pain, they are associated with serious safety concerns and many opioid-naïve patients fear taking them because of the potential for abuse and addiction. The data for NKTR-181 suggest that it is a transformational pain medicine that could fundamentally change how we treat patients with chronic pain conditions."
The SUMMIT-07 study compared twice-daily dosing of NKTR-181 tablets to placebo in the treatment of over 600 patients with moderate to severe chronic low back pain who were new to opioid therapy (opioid-naïve). The clinical trial met the primary efficacy endpoint of the study in demonstrating significantly improved chronic back pain relief with NKTR-181 compared to placebo (p=0.0019). Key secondary endpoints of the study were also met with high statistical significance.
Pain is one of the most common reasons people seek medical treatment.2 Low back pain is the second most common cause of disability for adults in the U.S. 3 Approximately 149 million work days are lost every year because of low back pain, with total costs estimated to be $100 to 200 billion a year (of which two-thirds is due to lost wages and lower productivity).4 A study published in the American Pain Society's The Journal of Pain in October 2014 estimated that 19 percent of the U.S. population, or 39 million people, suffer from some type of persistent pain.5
The Phase 3 SUMMIT-07 study used an enriched-enrollment randomized withdrawal (EERW) trial design in patients with moderate to severe chronic low back pain. The trial included an open-label titration period in which patients were titrated to a tolerated, effective dose of NKTR-181 (100 mg to 400 mg twice-daily). Following this open-label titration period, patients entered a double-blind, placebo-controlled treatment period in which they were randomized 1:1 to either continue to receive the tolerated, effective dose of NKTR-181 or to receive matching placebo (i.e. active drug was withdrawn) for a period of 12 weeks.
During the open-label titration period of the trial in which patients were titrated to a tolerated, effective dose of NKTR-181, average pain scores dropped by 65% (from 6.73 at screening to 2.32 at randomization, n=610).
The primary endpoint of the study was mean change in the weekly average pain score in the double-blind randomized treatment period from baseline (end of open-label titration period) to week 12 (end of double-blind randomized treatment period).
Primary and key sensitivity analyses:
During the double-blind randomized treatment period of the trial, average pain scores increased more in the placebo arm versus NKTR-181 at week 12 from randomization baseline (1.46, placebo versus 0.92, NKTR-181, p=0.0019, n=610).
83% of patients completed the 12-week double-blind randomized treatment period and for these study completers, average pain scores increased more in the placebo arm versus NKTR-181 at week 12 from baseline (1.25, placebo versus 0.56, NKTR-181, p < 0.0001, n=504).
Key secondary endpoints:
A statistically significant proportion of patients on NKTR-181 experienced pain reductions greater than 30% compared to placebo (71.2% versus 57.1%; p=0.0003).
A statistically significant proportion of patients on NKTR-181 experienced pain reductions greater than 50% compared to placebo (51.1% versus 37.9%; p=0.001).
A statistically significant proportion of patients on NKTR-181 reported their general overall status and quality of life as "improved" or "very much improved" compared to placebo as assessed by the Patient's Global Impression of Change (PGIC) of pain medication questionnaire (51.5% versus 33.2%; p < 0.0001).
The study also demonstrated that NKTR-181 had a favorable safety profile and was well tolerated. During the double-blind randomized treatment period, the most commonly reported adverse events for patients ( > 5%) were nausea (10.4%) and constipation (8.7%) in the NKTR-181 arm as compared to nausea (6.0%) and constipation (3.0%) in the placebo arm.
Patients randomized to NKTR-181 as compared to placebo reported more favorable sleep outcomes as measured by the validated Medical Outcomes Study (MOS) Sleep Scale, which captures debilitating aspects of sleep most strongly associated with chronic pain. Patients reported better overall quality of sleep with less sleep problems on NKTR-181 versus placebo. There were no differences in daytime sleepiness on NKTR-181 versus placebo.
Full data from the SUMMIT-07 study will be presented at a medical meeting in the second half of 2017.
"As a new molecule, NKTR-181 has a highly differentiated profile with the potential to be one of the most important advancements in pain medicine," said Howard W. Robin, President and CEO of Nektar Therapeutics. "Given the seriousness of the current opioid epidemic in the U.S. and the significant number of people battling chronic pain, we are committed to bringing this new molecule to patients and physicians as quickly as possible."
In March 2017, results from a separate human abuse potential trial of NKTR-181 were published in the American Academy of Pain Medicine's journal of Pain Medicine. The human abuse potential study assessed the relative abuse potential of a range of therapeutic doses of NKTR-181 (100 mg to 400 mg), the same dose range evaluated in the Phase 3 SUMMIT-07 efficacy trial. All doses of NKTR-181 tested for abuse potential were rated similarly to placebo in "drug liking" and "feeling high" scores and had highly statistically significant lower "drug liking" scores and reduced "feeling high" scores as compared to 40 mg oxycodone (p < 0.0001). In addition, all doses of NKTR-181 also scored lower on sleepiness when compared to 40 mg oxycodone (p < 0.0001).
"It is clear that there is a pressing societal need for better and safer analgesics," said Dr. Jack Henningfield, Ph.D., Adjunct Professor of Behavioral Biology in the Department of Psychiatry and Behavioral Sciences at the Johns Hopkins University School of Medicine and Head of Health Policy and Abuse Liability at Pinney & Associates in Bethesda, MD. "In the human abuse potential study, even the highest analgesic dose of NKTR-181 was barely distinguishable from placebo with respect to both drug-liking and feeling high and these effects were modest compared to those produced by oxycodone. Drug-liking and feeling high are two of the most important metrics that help us understand the abuse potential of a medicine. Importantly, as NKTR-181 is a new chemical entity, the properties of NKTR-181 are inherent to its molecular structure and independent of any abuse-deterrent formulation. Today's reported efficacy and safety results, along with the human abuse potential data published this past week in Pain Medicine, suggest NKTR-181 may be a major advance towards safer opioid therapy for the treatment of moderate to severe chronic pain."
New updates on NKTR-181 - the novel opioid for chronic pain, presented by Stephen Doberstein , Senior Vice President and Chief Scientific Officer from Nektar Therapeutics. More information on the talk at the 17th Annual Pain Therapeutics summit in London are available at http://www.pain-therapeutics.co.uk/ihub
Love this stock
Strategy on opioid abuse
Stephen Doberstein Senior Vice President and Chief Scientific Officer from Nektar Therapeutics will be chairing the 16th annual Pain Therapeutics conference in May! Engineering brain entry rate to reduce opioid abuse indicating that Nektar are on the cusp of some major developments in Pain drugs. Pain Therapeutics
Moving in the right direction atleast
$NKTR recent news/filings
bullish 15.85
## source: finance.yahoo.com
Thu, 03 Dec 2015 16:04:18 GMT ~ Nektar Therapeutics Earnings Q3, 2015
read full: http://www.capitalcube.com/blog/index.php/nektar-therapeutics-earnings-q3-2015/
*********************************************************
Mon, 30 Nov 2015 15:21:00 GMT ~ Baxalta Announces U.S. Availability of ADYNOVATE, A New Treatment for Adult Patients with Hemophilia A With a Simple, Twice-Weekly Dosing Schedule
[PR Newswire] - BANNOCKBURN, Ill., Nov. 30, 2015 /PRNewswire/ -- Baxalta Incorporated (NYSE: BXLT), a global biopharmaceutical leader dedicated to delivering transformative therapies to patients with orphan diseases and ...
read full: http://finance.yahoo.com/news/baxalta-announces-u-availability-adynovate-152100847.html
*********************************************************
Wed, 25 Nov 2015 13:16:34 GMT ~ Hedge Funds Aren’t Crazy About Nektar Therapeutics (NKTR) Anymore
read full: http://www.insidermonkey.com/blog/hedge-funds-arent-crazy-about-nektar-therapeutics-nktr-anymore-388609/
*********************************************************
Tue, 17 Nov 2015 21:31:00 GMT ~ Get Ready for Nektar Therapeutics (NKTR) Stock to Break Out
read full: http://www.thestreet.com/story/13369571/1/get-ready-for-nektar-nktr-stock-to-break-out.html?puc=yahoo&cm_ven=YAHOO
*********************************************************
Tue, 17 Nov 2015 21:01:00 GMT ~ Why Nektar Therapeutics Skyrocketed 30% Higher in October
read full: http://www.fool.com/investing/general/2015/11/17/why-nektar-therapeutics-skyrocketed-30-higher-in-o.aspx?source=eogyholnk0000001&utm_source=yahoo&utm_medium=feed&utm_campaign=article
*********************************************************
$NKTR charts
basic chart ## source: stockcharts.com
basic chart ## source: stockscores.com
big daily chart ## source: stockcharts.com
big weekly chart ## source: stockcharts.com
$NKTR company information
## source: otcmarkets.com
Link: http://www.otcmarkets.com/stock/NKTR/company-info
Ticker: $NKTR
OTC Market Place: Not Available
CIK code: 0000906709
Company name: Nektar Therapeutics
Company website: http://www.nektar.com
Incorporated In: DE, USA
$NKTR share structure
## source: otcmarkets.com
Market Value: $2,029,795,368 a/o Dec 03, 2015
Shares Outstanding: 133,451,372 a/o Oct 29, 2015
Float: Not Available
Authorized Shares: Not Available
Par Value: No Par Value
$NKTR extra dd links
Company name: Nektar Therapeutics
Company website: http://www.nektar.com
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/NKTR/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/NKTR/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=NKTR+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=NKTR+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=NKTR+Industry
## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/NKTR/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/NKTR/news - http://finance.yahoo.com/q/h?s=NKTR+Headlines
## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/NKTR/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/NKTR/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/NKTR/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/NKTR/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/NKTR/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/NKTR/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/NKTR/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/NKTR/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=NKTR+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/NKTR
DTCC (dtcc.com): http://search2.dtcc.com/?q=Nektar+Therapeutics&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Nektar+Therapeutics
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Nektar+Therapeutics&x=0&y=0
WHOIS (domaintools.com): http://whois.domaintools.com/http://www.nektar.com
Alexa (alexa.com): http://www.alexa.com/siteinfo/http://www.nektar.com#
Corporate website internet archive (archive.org): http://web.archive.org/web/*/http://www.nektar.com
## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/NKTR/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/NKTR
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/NKTR/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/NKTR/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/NKTR/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000906709&owner=exclude&count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/NKTR/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/NKTR/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/NKTR/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/NKTR/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=NKTR&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=NKTR
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/NKTR/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=NKTR+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=NKTR+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=NKTR
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=NKTR
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=NKTR+Cash+Flow&annual
## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/NKTR/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=NKTR+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/NKTR.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=NKTR
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/NKTR/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/NKTR/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/NKTR/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/NKTR/insider-transactions
## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/NKTR
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/NKTR
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/NKTR:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=NKTR
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=NKTR
$NKTR DD Notes ~ http://www.ddnotesmaker.com/NKTR
Followers
|
38
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
295
|
Created
|
10/20/05
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |